File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1007/s00277-002-0552-6
- Scopus: eid_2-s2.0-0036938435
- PMID: 12454706
- WOS: WOS:000179992200010
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Two cases of therapy-related acute promyelocytic leukemia (t-APL) after mantle cell lymphoma and gestational trophoblastic disease
Title | Two cases of therapy-related acute promyelocytic leukemia (t-APL) after mantle cell lymphoma and gestational trophoblastic disease |
---|---|
Authors | |
Keywords | Arsenic Gestational trophoblastic disease Mantle cell lymphoma Secondary APL |
Issue Date | 2002 |
Publisher | Springer Verlag. The Journal's web site is located at http://link.springer.de/link/service/journals/00277/index.htm |
Citation | Annals Of Hematology, 2002, v. 81 n. 11, p. 659-661 How to Cite? |
Abstract | We report two cases of secondary acute promyelocytic leukemia (APL). One patient presented with concurrent APL and missed abortion 1 year after etoposide-based chemotherapy for gestational trophoblastic disease. A prolonged complete remission was achieved with standard chemotherapy. An elderly man developed APL 1 year after alkylator-based chemotherapy for mantle cell lymphoma (MCL). A complete clinical and molecular remission was obtained with chemotherapy and all-trans retinoic acid, followed by arsenic consolidation. Concomitant molecular relapse of APL and MCL clones was detected at 1 year, both of which responded to oral arsenic therapy. High-dose epipodophyllin is a dose risk for secondary APL, but alkylating agents may also be implicated. For patients with a history of active malignancy and heavy previous chemotherapy exposure, the use of nontoxic arsenic therapy appeared to be effective and prudent. |
Persistent Identifier | http://hdl.handle.net/10722/162647 |
ISSN | 2023 Impact Factor: 3.0 2023 SCImago Journal Rankings: 0.912 |
ISI Accession Number ID | |
References |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Au, WY | en_HK |
dc.contributor.author | Ma, SK | en_HK |
dc.contributor.author | Chung, LP | en_HK |
dc.contributor.author | Chim, CS | en_HK |
dc.contributor.author | Kwong, YL | en_HK |
dc.date.accessioned | 2012-09-05T05:22:02Z | - |
dc.date.available | 2012-09-05T05:22:02Z | - |
dc.date.issued | 2002 | en_HK |
dc.identifier.citation | Annals Of Hematology, 2002, v. 81 n. 11, p. 659-661 | en_HK |
dc.identifier.issn | 0939-5555 | en_HK |
dc.identifier.uri | http://hdl.handle.net/10722/162647 | - |
dc.description.abstract | We report two cases of secondary acute promyelocytic leukemia (APL). One patient presented with concurrent APL and missed abortion 1 year after etoposide-based chemotherapy for gestational trophoblastic disease. A prolonged complete remission was achieved with standard chemotherapy. An elderly man developed APL 1 year after alkylator-based chemotherapy for mantle cell lymphoma (MCL). A complete clinical and molecular remission was obtained with chemotherapy and all-trans retinoic acid, followed by arsenic consolidation. Concomitant molecular relapse of APL and MCL clones was detected at 1 year, both of which responded to oral arsenic therapy. High-dose epipodophyllin is a dose risk for secondary APL, but alkylating agents may also be implicated. For patients with a history of active malignancy and heavy previous chemotherapy exposure, the use of nontoxic arsenic therapy appeared to be effective and prudent. | en_HK |
dc.language | eng | en_US |
dc.publisher | Springer Verlag. The Journal's web site is located at http://link.springer.de/link/service/journals/00277/index.htm | en_HK |
dc.relation.ispartof | Annals of Hematology | en_HK |
dc.subject | Arsenic | en_HK |
dc.subject | Gestational trophoblastic disease | en_HK |
dc.subject | Mantle cell lymphoma | en_HK |
dc.subject | Secondary APL | en_HK |
dc.subject.mesh | Adult | en_US |
dc.subject.mesh | Aged | en_US |
dc.subject.mesh | Antineoplastic Agents, Alkylating - Adverse Effects - Therapeutic Use | en_US |
dc.subject.mesh | Arsenicals - Therapeutic Use | en_US |
dc.subject.mesh | Etoposide - Adverse Effects - Therapeutic Use | en_US |
dc.subject.mesh | Female | en_US |
dc.subject.mesh | Gestational Trophoblastic Disease - Drug Therapy - Pathology | en_US |
dc.subject.mesh | Humans | en_US |
dc.subject.mesh | Leukemia, Promyelocytic, Acute - Chemically Induced - Drug Therapy - Etiology | en_US |
dc.subject.mesh | Lymphoma, Mantle-Cell - Drug Therapy - Pathology | en_US |
dc.subject.mesh | Male | en_US |
dc.subject.mesh | Neoplasms, Second Primary - Drug Therapy - Etiology | en_US |
dc.subject.mesh | Oxides - Therapeutic Use | en_US |
dc.subject.mesh | Pregnancy | en_US |
dc.subject.mesh | Tretinoin - Therapeutic Use | en_US |
dc.title | Two cases of therapy-related acute promyelocytic leukemia (t-APL) after mantle cell lymphoma and gestational trophoblastic disease | en_HK |
dc.type | Article | en_HK |
dc.identifier.email | Chung, LP: lpchung@hkucc.hku.hk | en_HK |
dc.identifier.email | Kwong, YL: ylkwong@hku.hk | en_HK |
dc.identifier.authority | Chung, LP=rp00249 | en_HK |
dc.identifier.authority | Kwong, YL=rp00358 | en_HK |
dc.description.nature | link_to_subscribed_fulltext | en_US |
dc.identifier.doi | 10.1007/s00277-002-0552-6 | en_HK |
dc.identifier.pmid | 12454706 | - |
dc.identifier.scopus | eid_2-s2.0-0036938435 | en_HK |
dc.identifier.hkuros | 77876 | - |
dc.relation.references | http://www.scopus.com/mlt/select.url?eid=2-s2.0-0036938435&selection=ref&src=s&origin=recordpage | en_HK |
dc.identifier.volume | 81 | en_HK |
dc.identifier.issue | 11 | en_HK |
dc.identifier.spage | 659 | en_HK |
dc.identifier.epage | 661 | en_HK |
dc.identifier.isi | WOS:000179992200010 | - |
dc.publisher.place | Germany | en_HK |
dc.identifier.scopusauthorid | Au, WY=7202383089 | en_HK |
dc.identifier.scopusauthorid | Ma, SK=37020910400 | en_HK |
dc.identifier.scopusauthorid | Chung, LP=24315879100 | en_HK |
dc.identifier.scopusauthorid | Shim, CS=7103280886 | en_HK |
dc.identifier.scopusauthorid | Kwong, YL=7102818954 | en_HK |
dc.identifier.issnl | 0939-5555 | - |